China-Biotics Attended National Probiotics Seminar

Dec 07, 2010, 06:00 ET from China-Biotics, Inc.

SHANGHAI, Dec. 7, 2010 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. ("China-Biotics" or "the Company"), (Nasdaq: CHBT) the leading developer, manufacturer and distributor of probiotics products in China, today announced that a delegation from the Company's research and development department presented at the National Probiotics Research and Development, New Application and Equipment seminar in Hangzhou, China on November 21st.

The seminar was organized and hosted by the National High-Tech Industrialization Association. More than 180 research and development professionals from global industry leaders and other probiotics companies participated in the event.

The Company's R&D specialists presented on bifidobacterium infantis, focusing on the fermentation techniques, quality assurance on product stability, and the application of bifidobacterium infantis in health food products.

Mr. Jinan Song, Chairman and CEO of China-Biotics, commented, "Research and development and the application of probiotics is accelerating in China as consumers continue to grasp the beneficial effects of probiotics. Meanwhile, the Chinese government is also poised to implement stricter enforcement to reduce the use of antibiotics use in animal feed. As a result, the probiotics industry is experiencing linear growth with rising popularity among consumers and favorable policy supports. Advancement in production techniques and the gradual standardization of industry practices have laid the foundation for more dairy and animal producers to embrace probiotics."

About China-Biotics

China-Biotics, Inc. ("China-Biotics" or "the Company"), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements in China. Through its wholly owned subsidiaries, Shanghai Shining Biotechnology Co., Ltd. and Growing Bioengineering (Shanghai) Co. Ltd., the Company develops and produces its proprietary product portfolio. Currently, the retail products are sold OTC mainly through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang province. The Company also sells bulk products to institutional customers such as dairy and animal feed producers, as well as pharmaceutical companies. In February 2010, China-Biotics began its commercial production in China's largest probiotics production facility to meet growing demand in China. For more information, please visit http://www.chn-biotics.com.

Safe Harbor Statement

The information in this release contains forward-looking statements which involve risks and uncertainties, including statements regarding the Company's capital needs, business strategy and expectations. Any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements, which may be identified by terminology such as "may," "should," "will," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," "forecast," "project," or "continue," the negative of such terms or other comparable terminology. Readers should not rely on forward-looking statements as predictions of future events or results. Any or all of the Company's forward-looking statements may turn out to be wrong. They can be affected by inaccurate assumptions, risks and uncertainties and other factors which could cause actual events or results to be materially different from those expressed or implied in the forward-looking statements. In evaluating these statements, readers should consider various factors, including the risks described in "Item 1A. Risk Factors" beginning on page 17 and elsewhere in the Company's 2010 Annual Report on Form 10-K. These factors may cause the Company's actual results to differ materially from any forward-looking statement. In addition, new factors emerge from time to time and it is not possible for the Company to predict all factors that may cause actual results to differ materially from those contained in any forward- looking statements. The Company disclaims any obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this document, except as required by applicable law.

Contact:

Travis Cai

Chief Financial Officer

China-Biotics, Inc.

traviscai@chn-biotics.com

Shiwei Yin/Dixon Chen

Grayling

646-284-9474

shiwei.yin@grayling.com

dixon.chen@grayling.com

SOURCE China-Biotics, Inc.



RELATED LINKS

http://www.chn-biotics.com